Exploring the complexity of the HIV-1 fitness landscape

PLoS Genetics

Volumn 8, Issue 3, 2012, Pages

  Kouyos, Roger D ^a,b   Leventhal, Gabriel E ^a   Hinkley, Trevor ^a   Haddad, Mojgan ^c   Whitcomb, Jeannette M ^c   Petropoulos, Christos J ^c   Bonhoeffer, Sebastian ^a  

^a ETH ZURICH   (Switzerland)

^b PRINCETON UNIVERSITY   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADAPTATION; ARTICLE; CONTROLLED STUDY; EPISTASIS; FITNESS LANDSCAPE; GENETIC CORRELATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MOLECULAR EVOLUTION; NONHUMAN; PREDICTION; VIRUS REPLICATION; EVOLUTION; GENETIC SELECTION; GENETICS; HUMAN; MUTATION; REPRODUCTIVE FITNESS; THEORETICAL MODEL;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADAPTATION, PHYSIOLOGICAL; BIOLOGICAL EVOLUTION; GENETIC FITNESS; HIV-1; HUMANS; MODELS, THEORETICAL; MUTATION; SELECTION, GENETIC;

EID: 84859257158     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1002551     Document Type: Article

References (30)

1. Wright S, (1931) Evolution in Mendelian Populations. Genetics 16: 97-159.
2. Collins JA, Thompson MG, Paintsil E, Ricketts M, Gedzior J, et al. (2004) Competitive Fitness of Nevirapine-Resistant Human Immunodeficiency Virus Type 1 Mutants. J Virol 78: 603-611.
3. Deforche K, Camacho R, Van Laethem K, Lemey P, Rambaut A, et al. (2008) Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment. Bioinformatics 24: 34-41.
4. Poelwijk FJ, Kiviet DJ, Weinreich DM, Tans SJ, (2007) Empirical fitness landscapes reveal accessible evolutionary paths. Nature 445: 383-386.
5. Weinreich DM, Delaney NF, DePristo MA, Hartl DL, (2006) Darwinian Evolution Can Follow Only Very Few Mutational Paths to Fitter Proteins. Science 312: 111-114.
6. Whitlock MC, Bourguet D, (2000) Factors affecting the genetic load in Drosophila: synergistic epistasis and correlations among fitness components. Evolution 54: 1654-1660.
7. Franke J, Klozer A, de Visser JA, Krug J, Evolutionary accessibility of mutational pathways. PLoS Comput Biol 7: e1002134 doi:10.1371/journal.pcbi.1002134.
8. O'Maille PE, Malone A, Dellas N, Andes Hess B Jr, Smentek L, et al. (2008) Quantitative exploration of the catalytic landscape separating divergent plant sesquiterpene synthases. Nat Chem Biol 4: 617-623.
9. Fontana W, Stadler PF, Bornberg-Bauer EG, Griesmacher T, Hofacker IL, et al. (1993) RNA folding and combinatory landscapes. Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics 47: 2083-2099.
10. Pitt JN, Ferre-DAmare AR, Rapid Construction of Empirical RNA Fitness Landscapes. Science 330: 376-379.
11. Lunzer M, Miller SP, Felsheim R, Dean AM, (2005) The Biochemical Architecture of an Ancient Adaptive Landscape. Science 310: 499-501.
12. Kauffman S, Levin S, (1987) Towards a general theory of adaptive walks on rugged landscapes. J Theor Biol 128: 11-45.
13. Weinberger E, (1990) Correlated and uncorrelated fitness landscapes and how to tell the difference. Biological Cybernetics 63: 325-336.
14. van Nimwegen E, (2006) Epidemiology. Influenza escapes immunity along neutral networks. Science 314: 1884-1886.
15. Fontana W, Schuster P, (1998) Continuity in evolution: on the nature of transitions. Science 280: 1451-1455.
16. Kimura M, (1983) The neutral theory of molecular evolution.: Cambridge University Press.
17. Koelle K, Cobey S, Grenfell B, Pascual M, (2006) Epochal evolution shapes the phylodynamics of interpandemic influenza A (H3N2) in humans. Science 314: 1898-1903.
18. Gavrilets S, (2004) Fitness Landscapes and the Origin of Species: Princeton University Press.
19. Bonhoeffer S, Chappey C, Parkin NT, Whitcomb JM, Petropoulos CJ, (2004) Evidence for positive epistasis in HIV-1. Science 306: 1547-1550.
20. Costanzo M, Baryshnikova A, Bellay J, Kim Y, Spear ED, et al. The genetic landscape of a cell. Science 327: 425-431.
21. Hinkley T, Martins J, Chappey C, Haddad M, Stawiski E, et al. (2011) A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase. Nat Genet 43: 487-489.
22. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, et al. (2010) Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 18: 156-163.
23. Martinez-Cajas JL, Wainberg MA, (2007) Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives. Antiviral Res 76: 203-221.
24. Doyon L, Tremblay S, Bourgon L, Wardrop E, Cordingley MG, (2005) Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res 68: 27-35.
25. Otto SP, Barton NH, (2001) Selection for recombination in small populations. Evolution 55: 1921-1931.
26. Keightley PD, Otto SP, (2006) Interference among deleterious mutations favours sex and recombination in finite populations. Nature 443: 89-92.
27. Fontana W, Konings DAM, Stadler PF, Schuster P, (1993) Statistics of Rna Secondary Structures. Biopolymers 33: 1389-1404.
28. Kouyos RD, von Wyl V, Hinkley T, Petropoulos CJ, Haddad M, et al. (2011) Assessing predicted HIV-1 replicative capacity in a clinical setting. PLoS Pathog 7: e1002321 doi:10.1371/journal.ppat.1002321.
29. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, et al. (2000) A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 44: 920-928.
30. Mayer JE, Montroll E, (1941) Molecular distribution. Journal of Chemical Physics 9: 2-16.